C4 Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 99
Employees
  • Stock Symbol
  • CCCC
Stock Symbol
  • Share Price
  • $23.19
  • (As of Tuesday Closing)

C4 Therapeutics General Information

Description

C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to eliminate disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 490 Arsenal Way
  • Suite 200
  • Watertown, MA 02472
  • United States
+1 (617) 000-0000

C4 Therapeutics Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

C4 Therapeutics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$23.19 $23.99 $22.08 - $51.21 $1.17B 48.6M 340K -$1.78

C4 Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 1,721,796 1,505,648
Revenue 33,969 33,195 21,381 19,364
EBITDA (86,783) (64,508) (33,857) (15,123)
Net Income (90,029) (66,335) (34,099) (15,711)
Total Assets 507,911 400,138 118,260 146,491
Total Debt 22,685 22,920 13,749 14,482
Public Fundamental Data provided by Morningstar, Inc. disclaimer

C4 Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore C4 Therapeutics‘s full profile, request access.

Request a free trial

C4 Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore C4 Therapeutics‘s full profile, request access.

Request a free trial

C4 Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
C4 Therapeutics Inc is a bio-pharmaceutical company. The company is focused on harnessing the body's natural regulation
Drug Discovery
Watertown, MA
99 As of 2020
00000
00000000 00000

00000 00

esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt i
0000 000000000
Watertown, MA
000 As of 0000
00.000
00000000 00.000

0000000

t amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliq
0000000000000
New Haven, CT
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

C4 Therapeutics Competitors (8)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Forma Therapeutics Formerly VC-backed Watertown, MA 000 00.000 00000000 00.000
0000000 Formerly VC-backed New Haven, CT 000 00000 000000 - 000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
0000000 0000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed Watertown, MA 000 00000 00000000 00000
You’re viewing 5 of 8 competitors. Get the full list »

C4 Therapeutics Patents

C4 Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020272978-A1 Tricyclic degraders of ikaros and aiolos Pending 12-Apr-2019 0000000000
CA-3130469-A1 Tricyclic degraders of ikaros and aiolos Pending 12-Apr-2019 0000000000
EP-3897631-A1 Targeted protein degradation Pending 20-Dec-2018 0000000000
EP-3846800-A1 Compounds for the degradation of brd9 or mth1 Pending 04-Sep-2018 0000000000
US-20210198256-A1 Compounds for the degradation of brd9 or mth1 Pending 04-Sep-2018 C07D471/04
To view C4 Therapeutics’s complete patent history, request access »

C4 Therapeutics Executive Team (18)

Name Title Board Seat Contact Info
Andrew Hirsch Chief Executive Officer & Board Member
William Mckee Chief Financial Officer, Finance & Treasurer, Finance
Lauren White Chief Financial Officer
Jolie Siegel JD Secretary, Administration & Chief Legal Officer, Legal
Kelly Schick Chief People Officer
You’re viewing 5 of 18 executive team members. Get the full list »

C4 Therapeutics Board Members (15)

Name Representing Role Since
Alain Cohen Cobro Ventures Board Member 000 0000
Andrew Hirsch C4 Therapeutics Chief Executive Officer & Board Member 000 0000
Bruce Downey JD Self Board Member 000 0000
Elena Prokupets Ph.D C4 Therapeutics Board Member 000 0000
Ken Anderson MD C4 Therapeutics Board Member 000 0000
You’re viewing 5 of 15 board members. Get the full list »

C4 Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial